PFIZER-E Drug Patent Profile
✉ Email this page to a colleague
When do Pfizer-e patents expire, and when can generic versions of Pfizer-e launch?
Pfizer-e is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in PFIZER-E is erythromycin stearate. There are one hundred and three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the erythromycin stearate profile page.
Summary for PFIZER-E
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 26 |
Clinical Trials: | 310 |
Patent Applications: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PFIZER-E at DailyMed |
Recent Clinical Trials for PFIZER-E
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Myovant Sciences GmbH | Phase 2 |
Dana-Farber Cancer Institute | Phase 2 |
Prostate Cancer Foundation | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for PFIZER-E
US Patents and Regulatory Information for PFIZER-E
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | PFIZER-E | erythromycin stearate | TABLET;ORAL | 061791-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | PFIZER-E | erythromycin stearate | TABLET;ORAL | 061791-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |